StreetInsider.com News Articles

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Sat, 28 Feb 2026 09:45:00 -0500

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms
99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalization
Strong evidence of bezuclastinib’s potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement

WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Sat, 28 Feb 2026 09:45:00 -0500

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms
99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalization
Strong evidence of bezuclastinib’s potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement

WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Sat, 28 Feb 2026 09:45:00 -0500

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms
99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalization
Strong evidence of bezuclastinib’s potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement

WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Sat, 28 Feb 2026 09:45:00 -0500

Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms
99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalization
Strong evidence of bezuclastinib’s potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement

WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on

Cogent (COGT) PT Raised to $35 at Baird

Thu, 19 Feb 2026 08:18:50 -0500

Baird analyst Colleen Kusy raised the price target on Cogent (NASDAQ: COGT) to $35.00 (from $34.00) while maintaining a Neutral rating.

Cogent (COGT) PT Raised to $52; Piper Sandler 'Remain Buyers Ahead of 2H26 Bezuclastinib Launch'

Wed, 18 Feb 2026 07:23:05 -0500

(Updated - February 18, 2026 7:23 AM EST)

Piper Sandler analyst Allison M. Bratzel raised the price target on Cogent (NASDAQ: COGT) to $52.00 (from $39.00) while maintaining an Overweight rating.

The analyst commented: "Remain Buyers Ahead of 2H26 Bezuclastinib Launch; Remain OW rated on COGT shares following Q425 reporting as the company shifts its primary focus to regulatory approvals and commercial readiness. With a hat trick of positive pivotal data for bezuclastinib in 2025, the narrative turns to execution. The NonAdvSM NDA has been submitted with acceptance expected this month, positioning the drug for potential approval and launch in 2H26. Additionally,

Cogent (COGT) PT Raised to $52; Piper Sandler 'Remain Buyers Ahead of 2H26 Bezuclastinib Launch'

Wed, 18 Feb 2026 07:23:05 -0500

(Updated - February 18, 2026 7:23 AM EST)

Piper Sandler analyst Allison M. Bratzel raised the price target on Cogent (NASDAQ: COGT) to $52.00 (from $39.00) while maintaining an Overweight rating.

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Commodore Capital LP

Tue, 17 Feb 2026 16:43:00 -0500

si-local-file:///var/storage/secattach/20260217/26014333.html

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Commodore Capital LP

Tue, 17 Feb 2026 16:43:00 -0500

si-local-file:///var/storage/secattach/20260217/26014333.html

Form S-8 Cogent Biosciences, Inc.

Tue, 17 Feb 2026 16:04:00 -0500

si-local-file:///var/storage/secattach/20260217/26012251.html

Form S-8 Cogent Biosciences, Inc.

Tue, 17 Feb 2026 16:04:00 -0500

si-local-file:///var/storage/secattach/20260217/26012251.html

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Kynam Capital Management, LP

Tue, 17 Feb 2026 12:43:00 -0500

si-local-file:///var/storage/secattach/20260217/26010256.html

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Kynam Capital Management, LP

Tue, 17 Feb 2026 12:43:00 -0500

si-local-file:///var/storage/secattach/20260217/26010256.html

Form 10-K Cogent Biosciences, Inc. For: Dec 31

Tue, 17 Feb 2026 09:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26008086.html

Form 10-K Cogent Biosciences, Inc. For: Dec 31

Tue, 17 Feb 2026 09:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26008086.html

Form 8-K Cogent Biosciences, Inc. For: Feb 17

Tue, 17 Feb 2026 08:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26006785.html

Form 8-K Cogent Biosciences, Inc. For: Feb 17

Tue, 17 Feb 2026 08:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26006785.html

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Tue, 17 Feb 2026 08:00:00 -0500

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026
PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026
Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meeting
Strong financial position with $901 million sufficient to fund operations into 2028